Kancera prepares clinical Phase IIa study in the Fractalkine project and has established collaboration with international pharmaceutical companies within the HDAC project.

Kancera has five drug projects in the portfolio. Kancera’s main resources are invested in the two Fractalkine projects. The further development of the HDAC project is externally financed through agreement with the pharmaceutical company Grünenthal. The PFKFB3 project is funded through an EU Horizon 2020 project and ROR1 mainly through academic collaborations.

Click here for a video recording of the presentation of KAND567 at ESC/WCC in Paris in September 2019. For educational purpose.


Selected Scientific publications